Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines

Infection and Immunity

Volumn 65, Issue 3, 1997, Pages 1053-1060

  Zollinger, Wendell D ^a   Moran, Ellen E ^a   Devi, Sarvamangala J N ^b   Frasch, Carl E ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE;

ADOLESCENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BACTERICIDAL ACTIVITY; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; MALE; MENINGITIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEPTICEMIA;

EID: 0031030047     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.3.1053-1060.1997     Document Type: Article

References (39)

1. Amir, J., M. G. Scott, M. H. Nahm, and D. M. Granoff. 1990. Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b. J. Infect. Dis. 162:163-171.
2. Amir, J., X. Liang, and D. M. Granoff. 1990. Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b. Pediatr. Res. 27:358-364.
3. Azmi, F. H., A. H. Lucas, H. L. Spiegelberg, and D. M. Granoff. 1995. Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain. Infect. Immun. 63:1906-1913.
4. 197 via adipic acid dihydrazide. Vaccine 1:463-470.
5. Devi, S. J. N., J. B. Robbins, and R. Schneerson. 1991. Antibodies to poly[(2→8)-α-N-acetylneuraminic acid] and poly[(2→9)-α-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc. Natl. Acad. Sci. USA 88:7175-7179.
6. Devi, S. J. N., C. E. Frasen, W. Zollanger, and P. J. Snoy. 1994. Immunization of juvenile rhesus monkeys with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines, p. 427-429. In J. S. Evans, S. E. Yost, M. C. J. Maiden, and I. M. Feavers (ed.), Proceedings of the Ninth International Pathogenic Neisseria Conference. SSC, Reading, England.
7. Devi, S. J. N., U. Hayat, C. E. Frasch, A. S. Kreger, and J. G. Morris, Jr. 1995. Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model. Infect. Immun. 63:2906-2911.
8. Devi, S. J. N., A. Karpas, and C. E. Frasch. 1996. Binding diversity of monoclonal antibodies to α(2→8) potysialic acid conjugated to outer membrane vesicle via adipic acid dihydrazide. FEMS Immunol. Med. Microbiol. 14:211-220.
9. Devi, S. J. N., W. D. Zollinger, P. J. Snoy, J. Y. Tai, P. Costantini, F. Norelli, R. Rappuoli, and C. E. Frasch. 1997. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugale vaccines in juvenile rhesus monkeys. Infect. Immun. 65:1045-1052.
10. Ey, P. L., G. J. Russell-Jones, and C. R. Jenkin. WHO. Isotypes of mouse IgG. I. Evidence for non-complement fixing IgG1 antibodies and characterization of their interference with IgG2 sensitization of target red blood cells for lysis by complement. Mol. Immunol. 17:699-710.
11. Frasch, C. E. 1995. Vaccines: past, present and future prospects, p. 245-283. In K., A. V. Cartwright (ed.), Meningocoecal disease. Wiley & Sons, New York, N.Y.
12. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningocoecus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
13. Gotschlich, E. C., T. Y. Liu, and M. S. Artenstein. 1969. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J. Exp. Med. 129:1347-1366.
14. Griffis, J. M., and D. K. Goroff. 1982. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J. Immunol. 130:2882-2885.
15. Jennings, H. J., C. Lugowski, and F. E. Ashton. 1984. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as a route to a potential vaccine against group B Neisseria meningitidis. Infect. Immun. 43:407-412.
16. Jennings, H. J., R. Roy, and A. Gamian. 1986. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137: 1708-1713.
17. Jennings, H. J., A. Gamian, F. Michon, and F. E. Ashton. 1989. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1. J. Immunol. 142:3585-3591.
18. Kasper, D. L., J. L. Winkelhake, W. D. Zollinger, B. L. Brandt, and M. S. Artenstein. 1973. Immunochemical similarity between polysaccharide antigens of Escherichia coli O7:K1(L):NM and group B Neisseria meningitidis. J. Immunol. 110:262-268.
19. Lifely, M. R., C. Moreno, and J. C. Lindon. 1987. An integrated molecular and immunological approach towards a meningococcal group B vaccine. Vaccine 5:11-26.
20. Lifely, M. R., S. C. Roberts, W. M. Shephard, J. Esdaile, Z. Wang, A. Cleverly, A. A. Aulaqi, and C. Moreno. 1991. Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins. Vaccine 9:60-66.
21. Lifely, M. R., and J. Esdaile. 1991. Specificity of the immune response to the group B Neisseria meningitidis. Immunology 74:490-496.
22. Mandrell, R. E., F. H. Azmi, and D. M. Granoff. 1995. Complement-mediated bactericidal activity of human antibodies to poly α2→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis. 172:1279-1289.
23. Moran, E. E., B. L. Brandt, and W. D. Zollinger. 1994. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:5290-5295.
24. Raff, H. V., D. Devereux, W. Shuford, D. Abbott-Brown, and G. Maloney. 1988. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections. J. Infect. Dis. 157:118-126.
25. Rosenquist, E., E. A. Hoiby, G. Bjune, P. Brandtzaeg, K. Bryn, O. Closs, and L. O. Froholm. 1990. Antibodies against meningococcal lipopolysaccharides after vaccination and meningococcal disease, p. 105. Seventh International Pathogenic Neisseria Conference. Walter de Gruyter and Co., Berlin, West Germany.
26. Rosenquist, E., E. A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Ronnild, G. Bjune, and H. Nokleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
27. Ross, S. C., P. J. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement deficient individuals. J. Infect. Dis. 155:1266-1275.
28. Sehlesinger, Y., D. M. Granoff, and the Vaccine Study Group. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 267:1489-1494.
29. Tai, J. Y., F. Michon, and P. C. Fusco. 1995. Antibody-dependent, complement-mediated bactericidal activity elicited by group B meningococcal conjugate vaccines in mice and nonhuman primates, abstr. G3, p. 159. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Verheul, A. F. M., J. A. M. Van Gaans, E. J. H. Wiertz, H. Snippe, J. Verhoef, and J. T. Poolman. 1993. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specitic bactericidal antibodies in mice: influence of adjuvants. Infect. Immun. 61:187-196.
31. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides, p. 83-91. In R. I. Whistler (ed.). Methods in carbohydrate chemistry, vol. V. Academic Press, Ltd., New York, N.Y.
32. World Health Organization Expert Committee on Biological Standardization. 1976. Requirements for meningococcal poiysaccharide vaccine, p. 51-75. World Health Organization Report Series 594. World Health Organization, Albany, N.Y.
33. Zollinger, W. D. Unpublished data.
34. Zollinger, W. D., R. E. Mandrell, J. M. Griffiss, P. Altieri, and S. Herman. 1979. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogcnic in man. J. Clin. Invest. 63:836-848.
35. Zollinger, W. D., J. E. Boslego, C. E. Frasch, and L. O. Froholm. 1984. Safety of vaccines containing meningococcal group B polysaccharide. Lancet ii:166.
36. Zollinger, W. D., and R. E. Mandrell. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264.
37. Zollinger, W. D., B. L. Brandt, and E. C. Tramont. 1986. Immune response to Neisseria meningitidis. p. 346. In N. R. Rose and H. Friedman (ed.). Manual of clinical immunology. 3rd ed. American Society for Microbiology, Washington, D.C.
38. Zollinger, W. D., and E. E. Moran. 1991. Meningococcal vaccines-present and future. Trans. R. Soc. Trop. Med. Hyg. 85:37-43.
39. Zollinger, W. D., C. E. Frasch, S. J. N. Devi, E. E. Moran, and P. J. Snoy. 1994. Bactericidal antibody responses of juvenile rhesus monkeys to conjugate B polysaccharide vaccines, p. 441-442. In J. S. Evans, S. E. Yost, M. C. J. Maiden, and I. M. Feavers (ed.), Proceedings of the Ninth International Pathogenic Neisseria Conference. SSC, Reading, England.